🇺🇸 FDA

Company profile · Sponsor

BioXcel

BioXcel Therapeutics

BTAI · NYSE pharma NEW HAVEN, CT, USA
Pipeline
17
Drugs
0
Patents
8

Quick answer

BioXcel (BTAI) is a pharma company. headquartered in NEW HAVEN, CT, USA. listed on NYSE. NovaPharmaNews links 17 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker BTAI
Exchange NYSE
Company type pharma
Headquarters NEW HAVEN, CT, USA
SEC CIK 0001720893

Pipeline (17)

Search pipeline →

  1. BXCL501

    BioXcel

    Agitation

    phase 3 small molecule completed

    4 trials

  2. BXCL501

    BioXcel

    Agitation,Psychomotor

    phase 3 small molecule completed

    1 trial

  3. Sublingual film containing Dexmedetomidine (BXCL501)

    BioXcel

    Agitation Associated With Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  4. Sublingual film containing dexmedetomidine (BXCL501)

    BioXcel

    Agitation

    phase 3 small molecule completed

    1 trial

  5. BXCL501 Sublingual Film

    BioXcel

    Bipolar I Disorder

    phase 2 small molecule completed

    1 trial

  6. BXCL701

    BioXcel

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. BXCL701 plus Pembrolizumab

    BioXcel

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  8. Dexmedetomidine

    BioXcel

    Opioid Withdrawal

    phase 2 small molecule completed

    1 trial

  9. Dexmedetomidine sublingual film

    BioXcel

    Delirium

    phase 2 small molecule terminated

    1 trial

  10. Sublingual film containing Dexmedetomidine

    BioXcel

    Agitation,Psychomotor

    phase 2 small molecule completed

    1 trial

  11. BXCL501 80 Micrograms

    BioXcel

    Schizophrenia

    phase 1 small molecule active

    1 trial

  12. Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg

    BioXcel

    Alcohol Use Disorder (AUD)

    phase 1 small molecule active

    1 trial

  13. Placebo

    BioXcel

    Alcohol Use Disorder (AUD)

    phase 1 small molecule completed

    1 trial

  14. Sublingual film containing BXCL501 (Dexmedetomidine)

    BioXcel

    Agitation

    phase 1 small molecule completed

    1 trial

  15. Talabostat Mesylate

    BioXcel

    Cancer of Pancreas

    phase 1 small molecule terminated

    1 trial

  16. Dexmedetomidine

    BioXcel

    Schizophrenia Agitation

    approved small molecule active

    1 trial

  17. Sublingual film containing Igalmi

    BioXcel

    Bipolar Disorder

    approved small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12364683

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12138247

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11998528

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11998529

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11931340

    Use of sublingual dexmedetomidine for the treatment of agitation

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11890272

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is BioXcel?

BioXcel (BTAI) is a pharma company. headquartered in NEW HAVEN, CT, USA. listed on NYSE. NovaPharmaNews links 17 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does BioXcel sponsor?

We track 17 ClinicalTrials.gov-linked programs for BioXcel, including BXCL501 and 16 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does BioXcel company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.